ATOS News 1.30 Atossa Genetics Inc (ATOS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Atossa Genetics Inc (ATOS) 1.30 $ATOS

Atossa Genetics elects Ben R Chen as SVP of its Global Regulatory Affairs and Quality Assurance
M2 - Thu Apr 03, 6:18AM CDT
Breast health company Atossa Genetics (NASDAQ:ATOS) revealed on Wednesday the appointment of Ben R Chen as senior vice president of its Global Regulatory Affairs and Quality Assurance.

Ben R. Chen Joins Atossa Genetics as Senior Vice President of Global Regulatory Affairs and Quality Assurance
Marketwire - Wed Apr 02, 7:31AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Ben R. Chen has joined the Company as Senior Vice President of Global Regulatory Affairs and Quality Assurance, a newly created position. Mr. Chen will oversee all facets of Atossa's regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities, and all quality assurance matters.

Atossa Genetics Announces 2013 Financial Results and Provides Company Update
Marketwire - Thu Mar 27, 3:02PM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced 2013 financial results and provided an update on recent corporate developments.

Atossa Genetics to Announce 2013 Financial Results and Provide a Company Update on Thursday, March 27, 2014
Marketwire - Mon Mar 24, 7:30AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it will issue financial results and corporate developments for the fiscal year ended December 31, 2013, following the close of market on Thursday, March 27, 2014.

Personalized Medicine and Companion Diagnostic Market Discussed in New Report by Kelly Scientific Publications Available at MarketPublishers.com
PRWeb - Fri Mar 07, 12:03PM CST
During the last 20 years, the ongoing genetic advances have considerably facilitated the emergence of personalized medicine sector as an important player in the overall healthcare universe. Human genome sequencing has propelled the pharmacogenetics sector. Furthermore, personalized medicine also takes into account pharmacogenomics studies, where protein and genetic interactions yield the potential drug targets. The key objective of personalized medicine is to offer individualized care that is more effective and specific to the potential patients. Targeted and personalized medicine R&D efforts are aimed at increasing the efficiency of the therapeutic area via genetic testing along with companion diagnostics. The introduction of novel personalized medicine will likely reduce the frequency of adverse drug reactions and thus have a significant influence on health economics. Diagnostic and developmental companies are predicted to take benefit from lower discovery and commercialization costs, as well as from more specific market sub-types awaited in the years ahead.

Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Atossa Genetics to submit additional information to the US FDA for ForeCYTE Breast Aspirator
M2 - Wed Mar 05, 6:15AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) disclosed on Tuesday that the US Food and Drug Administration (FDA) has requested additional information related to the company's 510(k) application for the clearance of its ForeCYTE Breast Aspirator.

Atossa Genetics Inc. Announces FDA Response to 510(k) Submission for ForeCYTE Breast Aspirator
Marketwire - Tue Mar 04, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has received a request for additional information from the U.S. Food and Drug Administration (FDA) related to its 510(k) application for the ForeCYTE Breast Aspirator. Atossa plans to request an extension to the 30 day time limit by which a response must be provided to the FDA. If the request for an extension is granted, Atossa will have up to 180 days to provide a response to the FDA's questions. Atossa does not view the FDA's request for additional information as unusual or unexpected and will continue to work toward final clearance of the submission.

Atossa Genetics elects Richard I. Steinhart to board
M2 - Tue Mar 04, 5:10AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) revealed on Monday the addition of Richard I. Steinhart to its board of directors

Richard I. Steinhart Joins Atossa Genetics' Board of Directors
Marketwire - Mon Mar 03, 11:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), announced today that Richard I. Steinhart has joined the Company's Board of Directors and has been appointed a Member of the Audit Committee and Compensation Committee.

3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BMO Economics: Business Investment and Housing to Lift Illinois' Economy 2.5 Percent in 2014
Marketwire - Tue Feb 04, 7:01AM CST
While economic growth in Illinois was challenged last year by a softening in factory activity and exports, 2014 will see the economy improve at a 2.5 percent pace, according to the bi-annual U.S. State Monitor Report from BMO Economics.

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Certain Officers and Directors of Atossa Genetics, Inc.
Business Wire - Fri Jan 31, 10:31AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP today announced that it is investigating whether the board of directors of Atossa Genetics, Inc. (NASDAQ:ATOS) breached its fiduciary duties to shareholders related to Atossa's October 4, 2013 disclosure that it would be forced to recall its ForeCYTE Breast Health Test and Mammary Aspiration Specimen Cytology Test. The recall was necessary to address concerns raised by the U.S. Food and Drug Administration ("FDA" . The FDA previously alerted the Company to concerns regarding the recalled products back in February 2013, and those concerns may not have been addressed by Atossa.

Atossa Genetics Inc completes public offering of 5.834m units
M2 - Thu Jan 30, 3:30AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) reported on Wednesday the completion of its public offering of 5,834,234 units.

Atossa Genetics Inc. Announces Closing of a Public Offering of Common Stock and Warrants
Marketwire - Wed Jan 29, 4:00PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has closed a public offering of 5,834,234 units at a price to the public of $2.40 per unit. The Company has received approximately $14.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.

Real Good Solar Takes On New Name, Ticker Symbol and Strategy: Real Goods Solar Inc. (NASDAQ:RSOL), Atossa Genetics Inc. (NASDAQ: ATOS), Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP)
ACCESSWIRE - Tue Jan 28, 7:02AM CST
What makes a pioneering solar energy company change its name, ticker symbol and strategy after 36 years?

Atossa Genetics prices public offering at USD2.40 per unit
M2 - Mon Jan 27, 6:18AM CST
US-based breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Friday that it has priced its public offering of approximately 5.8m units.

Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
Marketwire - Fri Jan 24, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of $2.40 per unit. The Company has received commitments and indications for approximately $14.0 million in gross proceeds. The sale of the units is expected to close on or about January 29, 2014, subject to the satisfaction of customary closing conditions. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.

Atossa Genetics Inc proposes public offering of units
M2 - Fri Jan 24, 4:54AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Thursday that it plans to offer units consisting of shares of common stock and warrants in a public offering.

Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock and Warrants
Marketwire - Thu Jan 23, 3:15PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. While the offering is expected to price before 9:30 am EST on January 24, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc. will serve as the sole book-running manager for the offering.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 29

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 0

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 10

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 50

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

Ragie Launches Advanced Agent Ready Features for Developers

Updated Category News Views 253

Ragie Introduces Innovative Agent Ready Features Ragie is excited to present its latest advancement: the introduction of Agent Ready capabilities. This launch focuses on empowering developers with tools for creating intelligent, context-aware agents. Enhanced features like Agentic Retrieval and support for Right-to-Left (RTL) languages enhance accessibility and robust...

Continue Reading
JNR Stellarc 100K: A Game-Changer in Refillable Vapes

Updated Category News Views 200

Introducing the JNR Stellarc 100K Refillable Vape JNR has officially launched the JNR Stellarc 100K, a remarkable modular refillable vape system that promises to redefine the vaping experience. Engineered for extreme endurance and superior safety features, the Stellarc 100K is set to offer unparalleled value to its users. This advanced vape is not just another product; it...

Continue Reading
Xiao-I Corporation Shareholders Encouraged to Join Class Action

Updated Category News Views 86

Xiao-I Corporation Shareholders Encouraged to Join Class Action Recent events have led to significant concerns for shareholders of Xiao-I Corporation. With allegations of misleading statements and inadequate disclosures surfacing, many shareholders find themselves at a crossroads. It is essential for investors who purchased shares during a specific period to explore their...

Continue Reading
Assessing Bristol Myers Squibb: Analyst Insights and Future Prospects

Updated Category News Views 138

Bristol Myers Squibb: A Low Valuation Opportunity BofA Securities has recently upgraded Bristol Myers Squibb Co. (NYSE: BMY) from a Neutral position to a Buy rating, indicating a positive outlook for the company driven by strong near-term catalysts. Analyst Jason Gerberry highlighted a compelling risk-reward scenario, especially as the company anticipates a flat...

Continue Reading
Carrier's Q3 Performance and Future Outlook: Key Insights

Updated Category News Views 237

Carrier Global Corporation's Q3 Earnings Overview Carrier Global Corporation (NYSE: CARR), a prominent innovator in climate and energy solutions, recently released its third-quarter earnings, showcasing performance that exceeded market expectations. The results highlight not only the financial stability of the company but also the strategic adjustments made to navigate...

Continue Reading